Ratings by William Blair (Andy Hsieh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/5/2026 | Altimmune | ALT | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/10/2026 | Nektar Therapeutics | NKTR | Upgrade | Outperform (Market Perform) |
37.07 (70.70) |
90.72% | Details | |
| 1/13/2026 | Terns Pharmaceuticals | TERN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Outperform (N/A) |
13.98 (5.85) |
-58.15% | Details | |
| 11/13/2025 | Mersana | MRSN | Downgrade | Market Perform (Outperform) |
8.87 (29.08) |
227.85% | Details | |
| 11/3/2025 | Terns Pharmaceuticals | TERN | Upgrade | Outperform (Market Perform) |
8.26 (42.82) |
418.4% | Details | |
| 8/19/2025 | Viking Therapeutic | VKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2025 | Exelixis | EXEL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2025 | Corbus Pharmaceuticals | CRBP | New Coverage | Outperform (N/A) |
7.47 (8.01) |
7.23% | Details | |
| 2/28/2025 | Skye Bioscience | SKYE | New Coverage | Outperform (N/A) |
2.78 (0.72) |
-74.1% | Details | |
| 2/28/2025 | Zealand Pharma A/S | ZEAL | New Coverage | Market Perform (N/A) |
17.59 (17.59) |
0% | Details | |
| 2/28/2025 | Terns Pharmaceuticals | TERN | New Coverage | Market Perform (N/A) |
3.76 (8.26) |
119.68% | Details | |
| 2/28/2025 | Structure Therapeutics | GPCR | New Coverage | Outperform (N/A) |
19.88 (57.73) |
190.39% | Details | |
| 2/28/2025 | BioAge Labs Inc | BIOA | New Coverage | Market Perform (N/A) |
4.19 (20.29) |
384.25% | Details | |
| 2/27/2025 | Altimmune | ALT | New Coverage | Market Perform (N/A) |
5.94 (3.54) |
-40.4% | Details | |
| 2/6/2025 | Mersana | MRSN | New Coverage | Outperform (N/A) |
0.61 (8.87) |
1354.1% | Details | |
| 3/19/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Market Perform (Outperform) |
10.64 (21.55) |
102.54% | Details | |
| 12/26/2023 | RayzeBio | RYZB | Downgrade | Market Perform (Outperform) |
30.57 (62.49) |
104.42% | Details | |
| 12/12/2023 | Icosavax Inc. | ICVX | Downgrade | Market Perform (Outperform) |
10.49 (15.31) |
45.95% | Details | |
| 11/30/2023 | Immunogen Inc. | IMGN | Downgrade | Market Perform (Outperform) |
16.06 (31.25) |
94.58% | Details | |
| 10/6/2023 | RayzeBio | RYZB | New Coverage | Outperform (N/A) |
20.06 (62.49) |
211.52% | Details | |
| 10/4/2023 | POINT Biopharma Global Inc. | PNT | Downgrade | Market Perform (Outperform) |
6.68 (12.50) |
87.13% | Details | |
| 8/3/2023 | Aravive Inc. | ARAV | Downgrade | Market Perform (Outperform) |
1.31 (0.04) |
-96.95% | Details | |
| 6/26/2023 | FibroGen | FGEN | Downgrade | Market Perform (Outperform) |
16.05 (9.71) |
-39.5% | Details | |
| 2/21/2023 | Actinium Pharma | ATNM | Downgrade | Market Perform (Outperform) |
13.76 (1.20) |
-91.28% | Details | |
| 1/31/2023 | FibroGen | FGEN | Upgrade | Outperform (Market Perform) |
21.75 (9.71) |
-55.36% | Details | |
| 7/26/2022 | Seagen | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/6/2022 | Fusion Pharmaceuticals | FUSN | New Coverage | Outperform (N/A) |
2.46 (21.55) |
776.02% | Details | |
| 7/6/2022 | POINT Biopharma Global Inc. | PNT | New Coverage | Outperform (N/A) |
7.78 (12.50) |
60.67% | Details | |
| 3/14/2022 | Nektar Therapeutics | NKTR | Downgrade | Market Perform (Outperform) |
10.63 (37.07) |
248.73% | Details | |
| 8/23/2021 | Icosavax Inc. | ICVX | New Coverage | Outperform (N/A) |
34.09 (15.31) |
-55.09% | Details | |
| 9/18/2020 | Aravive Inc. | ARAv | New Coverage | Outperform (N/A) |
5.81 (0.04) |
-99.31% | Details | |
| 8/14/2020 | Pfenex Inc. | PFNX | Downgrade | Market Perform (Outperform) |
12.89 (12.75) |
-1.09% | Details | |
| 8/8/2019 | Actinium Pharma | ATNM | New Coverage | Outperform (N/A) |
0.21 (1.20) |
471.43% | Details | |
| 6/21/2019 | Exelixis | EXEL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2019 | FibroGen | FGEN | Downgrade | Market Perform (Outperform) |
46.41 (9.71) |
-79.08% | Details | |
| 4/1/2019 | Celgene | CELG | Downgrade | Market Perform (Outperform) |
94.34 (108.24) |
14.73% | Details | |
| 3/12/2019 | Pfenex Inc. | PFNX | Maintain | Outperform (N/A) |
|
Details |
